💊 Aurobindo Pharma 💊
📊About:
It is an Indian 💊Pharmaceutical Multinational company headquartered in Hyderabad. Listed in 1995 on the stock exchanges the company is a leader in semi-synthetic penicillin💊. With a presence in over 155+ countries, the company has 27💊 manufacturing and packaging facilities.
📊Financials:
❧ In the recent quarterly results net profit of the company📉 declined by 28% to Rs.576 Cr.
❧ Along with the net profit, revenue also declined by📉 3% to Rs.5809 Cr.
❧ Expenses were higher at Rs.5097.75 Cr compared to Rs.5011 Cr in the same period the previous year.
❧ US formulation revenue also declined by📉 4.7% to Rs.2728 Cr while Europe formulation revenue remained flat at 📉Rs.1540.7 Cr.
❧ Board announced an interim dividend of Rs.4.5 per equity share of Re1.
❧ Management is expecting a volume growth in the upcoming quarters.
❧ Considering the past performance, the company has good revenue and profit growth with good average operating margins of around 23% in the past 5 years.
📊Technicals:
❧ With the current sell-off, the chart structure looks weaker in many aspects.
❧ Bearish crossover can be seen with 📉8 EMA and 50 DMA levels on the charts.
❧ Stock is trading near its 📉52-week low and had corrected heavily from its higher levels
❧ More weakness can be observed in the stock hence short 📉 position can be initiated below 510 for target of Rs.490 with a stop loss of Rs.522
Disclaimer: The information mentioned above is only for educational purposes. Kindly contact your financial advisor before trading/investing 💰
Please post your views/queries in the comments below. 👇
❮
❯
